This post was originally published on this site Biotheranostics‘ Breast Cancer Index can help distinguish which breast cancer patients will derive a benefit from prolonged endocrine therapy — allowing those who don’t to stop treatment and avoid its unpleasant side effects, new data suggests. The findings were shared at the 2019 American Society of Clinical…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
Nanostics Launches Pivotal Study to Validate ClarityDX Prostate Diagnostic Test
This post was originally published on this site Nanostics has started a pivotal clinical study in Canada to validate ClarityDX Prostate, a new blood test for the early diagnosis of prostate cancer. The company says the diagnostic tool has the potential to spare many men from unnecessary biopsies and treatments. The study is part of…
Copiktra Induces Promising Clinical Activity in PTCL Patients, Phase 1 Trials Show
This post was originally published on this site Copiktra (duvesilib) shows promising clinical activity in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), inducing responses in 44% to 57% of patients included in Phase 1 trials. The findings were presented during an oral presentation, “Duvelisib, an oral dual PI3K‐δ,γ inhibitor, efficacy and safety in…
Report Identifies Proteins That Drive Spread in Castration-resistant PC
This post was originally published on this site Inhibiting the protein BRD4 can stop the migration of castration-resistant prostate cancer cells, regardless of the mechanism causing resistance to treatment, new research has shown. This suggests that BRD4 might be a therapeutic target to prevent metastasis (spread) in prostate cancer patients who have become resistant to…
FDA Grants Priority Review to GSK’s Zejula for Late Stage Ovarian Cancer
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has accepted the application of Tesaro, a GSK company, seeking to extend approval for Zejula (niraparib) to women with late stage ovarian cancer who have received three or more prior chemotherapy treatments. The potentially new indication will cover advanced ovarian,…
Selinexor Combo Yields Strong Responses in Difficult-to-treat Multiple Myeloma
This post was originally published on this site Selinexor in combination with dexamethasone and Pomalyst (pomalidomide) leads to strong and durable anti-cancer responses, without significant side effects, in patients with relapsed or refractory multiple myeloma who received at least two prior therapies, data from a Phase 1/2b trial show. The findings were presented in a poster…
NORD Honors Industry, Patient Advocates at Rare Impact Awards Gala
This post was originally published on this site A violinist with vasculitis, two Texas politicians and a pharmaceutical company whose marijuana-derived therapy helps kids with Dravet syndrome were among winners of the 2019 Rare Impact Awards. Officials of the National Organization for Rare Disorders (NORD) presented the awards during a June 22 dinner attended by…
Tislelizumab Produces Promising Anti-Cancer Activity in Advanced Nasopharyngeal Cancer Patients, Preliminary Data Show
This post was originally published on this site BeiGene’s investigational anti-PD-1 inhibitor tislelizumab is well-tolerated and showed early signs of efficacy in patients with advanced nasopharyngeal cancer, with more than 40% of patients achieving a response to treatment, preliminary Phase 2 results show. The findings were presented at the 2019 American Society of Clinical Oncology…
European Commission Approves Talzenna to Treat Some Breast Cancers
This post was originally published on this site The European Commission (EC) has approved Pfizer‘s Talzenna (talazoparib) for the treatment of patients with advanced forms of HER2-negative breast cancer with BRCA mutations who have been treated with chemotherapy — before or after surgery, with an anthracycline and/or a taxane — or were not eligible to…
Researchers Work to Create Screening Tool for Early or Pre-cancerous OC
This post was originally published on this site Researchers from Clemson University and doctors from South Carolina’s Prisma Health-Upstate are collaborating to develop a screening tool that can identify ovarian cancer in its earlier stages, or even before it arises. Ovarian cancer is one of the deadliest for women. The best way to increase survival…
Zanubrutinib-Gazyva Shows Promise for CLL/SLL, Follicular Lymphoma
This post was originally published on this site Zanubrutinib in combination with Gazyva (obinutuzumab) leads to clinically meaningful responses and is well-tolerated by patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and follicular lymphoma, a Phase 1b trial shows. The findings were announced at an oral presentation titled, “Zanubrutinib Plus Obinutuzumab in Patients with Chronic…
Keytruda Found to be Safe as Cancer Treatment for HIV Patients, Phase 1 Trial Shows
This post was originally published on this site The immune checkpoint inhibitor Keytruda (pembrolizumab) was found to be a safe treatment for different cancer types among people living with HIV, data from a Phase 1 trial show. The results are likely applicable to other immune checkpoint inhibitors targeting the same pathway as Keytruda, the investigators said. The…